How good a predictor the in vitro antibiogram is, of in vivo antibiotic efficacy? An in vitro - in vivo integrated approach

Conventional antimicrobial susceptibility testing, particularly the disc diffusion assay (DDA), provides a convenient means of assessing bacterial susceptibility to antibiotics. However, its ability to predict antibiotic efficacy in an infected host remains uncertain. This study investigated the relationship between DDA-derived inhibition zones and host-protective antibiotic activity using Caenorhabditis elegans infection models involving three bacterial pathogens: methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Clostridioides difficile. A total of 42 antibiotics were evaluated through DDA, while a separate panel of 75 antibiotics was screened using an automated C. elegans infection assay. Twenty-six antibiotics common to both panels were selected for comparative analysis. Gnotobiotic L3-L4 stage worms were challenged with individual pathogens in the presence of each antibiotic at a fixed concentration of 9.6 microgram/mL. Worm activity was quantified at 24, 48, and 72 h using an automated worm tracker system, with appropriate health, infection, vehicle, and antibiotic-toxicity controls. Overall, DDA-derived zone of inhibition (ZOI) diameters showed weak-to-moderate, pathogen- and time-dependent correlations with worm activity. At 24 h, Pearson's correlation coefficients ranged from -0.20 to 0.31 across the three pathogen-host systems, while at 48 h they ranged from -0.009 to 0.49. Notably, antibiotic rankings based on DDA and host-protective activity differed considerably. For example, against C. difficile, imipenem produced the largest inhibition zone (41 mm) but failed to protect worms at 24 and 48 h, whereas tobramycin, despite producing a smaller inhibition zone (26 mm), exhibited the highest early worm activity. Similar discrepancies were observed with the other pathogens. These findings demonstrate that DDA-derived susceptibility profiles do not consistently predict antibiotic-mediated protection in an infected host. The C. elegans model may therefore serve as a complementary whole-organism screening platform, providing additional functional information for prioritizing antimicrobial agents beyond conventional in vitro susceptibility testing.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.17.766954
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

How good a predictor the in vitro antibiogram is, of in vivo antibiotic efficacy? An in vitro - in vivo integrated approach

Vijay Kothari, Nidhi Thakkar, Mitva Vaghela, Bruce Blough
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Antibiotics Pharmacokinetics and Efficacy
preprint

How good a predictor the in vitro antibiogram is, of in vivo antibiotic efficacy? An in vitro - in vivo integrated approach

Vijay Kothari, Nidhi Thakkar, Mitva Vaghela, Bruce Blough
preprint en

Abstract

Conventional antimicrobial susceptibility testing, particularly the disc diffusion assay (DDA), provides a convenient means of assessing bacterial susceptibility to antibiotics. However, its ability to predict antibiotic efficacy in an infected host remains uncertain. This study investigated the relationship between DDA-derived inhibition zones and host-protective antibiotic activity using Caenorhabditis elegans infection models involving three bacterial pathogens: methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Clostridioides difficile. A total of 42 antibiotics were evaluated through DDA, while a separate panel of 75 antibiotics was screened using an automated C. elegans infection assay. Twenty-six antibiotics common to both panels were selected for comparative analysis. Gnotobiotic L3-L4 stage worms were challenged with individual pathogens in the presence of each antibiotic at a fixed concentration of 9.6 microgram/mL. Worm activity was quantified at 24, 48, and 72 h using an automated worm tracker system, with appropriate health, infection, vehicle, and antibiotic-toxicity controls. Overall, DDA-derived zone of inhibition (ZOI) diameters showed weak-to-moderate, pathogen- and time-dependent correlations with worm activity. At 24 h, Pearson's correlation coefficients ranged from -0.20 to 0.31 across the three pathogen-host systems, while at 48 h they ranged from -0.009 to 0.49. Notably, antibiotic rankings based on DDA and host-protective activity differed considerably. For example, against C. difficile, imipenem produced the largest inhibition zone (41 mm) but failed to protect worms at 24 and 48 h, whereas tobramycin, despite producing a smaller inhibition zone (26 mm), exhibited the highest early worm activity. Similar discrepancies were observed with the other pathogens. These findings demonstrate that DDA-derived susceptibility profiles do not consistently predict antibiotic-mediated protection in an infected host. The C. elegans model may therefore serve as a complementary whole-organism screening platform, providing additional functional information for prioritizing antimicrobial agents beyond conventional in vitro susceptibility testing.

bioRxiv (Cold Spring Harbor Laboratory)
Nirma University (IN), RTI International (US)
U.S. Department of Health and Human Services, Nirma University, National Institutes of Health
Good health and well-being
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon